Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Fig. 4

Health outcomes measures (combined b.i.d. and t.i.d. dosing). Adjusted mean change from baseline and unadjusted box and whisker plot of unadjusted change from baseline by treatment over time. a HAQ-DI. b FACIT fatigue. c Clinical disease activity index (CDAI). d Simple disease activity index (SDAI). b.i.d., twice daily; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire-Disability Index; t.i.d., three times daily

Back to article page